We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Advice for medical professionals to follow when assessing drivers with diabetes mellitus.
You may need to tell DVLA if you have diabetes, depending on the treatment you're getting
Cutaneous amyloidosis at the injection site has been reported in patients using insulin and this may affect glycaemic control. Remind patients to rotate injection sites within the same body region.
The MHRA continues to receive serious reports of harm associated with insulin leakage for the NovoRapid PumpCart prefilled insulin cartridge in the Accu-Chek Insight Insulin pump. In some patients, there were serious consequences arising from inadequate supply of insulin, including...
We have issued a National Patient Safety Alert following serious reports of harm associated with insulin leakage during use of the Accu-Chek Insight Insulin pump with NovoRapid PumpCart prefilled insulin cartridges. Patients should be moved onto alternative insulin pumps where...
The UK regulator has taken safety action to reduce risks associated with Roche Accu-Chek Insight Insulin Pumps by issuing a national safety alert and outlining recommendations for patients.
People with diabetes using a particular type of insulin pump and pre-filled insulin cartridges should insert their cartridges correctly to avoid them leaking and potentially giving an under-delivery of insulin.
The European Medicines Agency has advised that no change in recommendations for use is required at present.
(Medtronic) Risk due to incorrect selection and delivery of bolus amount. (MDA/2014/019)
Several new high strength insulin products are now on the market. The European Medicines Agency is consulting on guidance to minimise the risk of medication error.
(Roche Diagnostics Ltd) Increased risk that the vibration alarm will not work as a result of a changed component. (MDA/2014/008)
Novo Nordisk is recalling one batch as a precautionary measure due to the presence of particles in a small number of samples.
Employment Tribunal decision.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey.